Soleno Therapeutics, Inc. (SLNO) Q3 2025 Earnings Call Transcript
…
41,270€
10,58%
Echtzeit-Aktienkurs Soleno Therapeutics
Bid:
Ask:
Nachrichten zur Soleno Therapeutics Aktie
Soleno Therapeutics tumbles despite Q3 earnings, revenue beat By Investing.com
Soleno Therapeutics tumbles despite Q3 earnings, revenue beat…
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…
SOLENO (SLNO) REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into Soleno Therapeutics, Inc. and Encourages Investors to Contact the Firm
Scorpion Capital alleged Soleno’s sole product, Vykat XR, was overpriced and unsafe for children, causing shares to drop 7.4% to…
Soleno Therapeutics - FDA-Zulassung für Vykat XR markiert wichtigen Meilenstein!
Geschäftstreiber: Soleno Therapeutics (SLNO) hat sich auf die Entwicklung neuer Therapien und Medikamente für seltene Erkrankungen spezialisiert. Mit der FDA-Zulassung…
Soleno Therapeutics (SLNO) Drops Amid Critical Scorpion Report -- Hagens Berman
SLNO Investors with Losses Encouraged to Contact Hagens Berman SLNO Investors with Losses Encouraged to Contact Hagens Berman…
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, Sept. 23, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, Sept. 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
Soleno Therapeutics, Inc. (SLNO) is a Great Momentum Stock: Should You Buy?
Does Soleno Therapeutics, Inc. (SLNO) have what it takes to be a top stock pick for momentum investors? Lets find…
Soleno Therapeutics - FDA-Zulassung für Vykat XR markiert wichtigen Meilenstein!
Geschäftstreiber: Soleno Therapeutics (SLNO) hat sich auf die Entwicklung neuer Therapien und Medikamente für seltene Erkrankungen spezialisiert. Mit der FDA-Zulassung…
Soleno Therapeutics stock falls after pricing $200 million offering By Investing.com
Soleno Therapeutics stock falls after pricing $200 million offering…
Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock
REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq:SLNO), a biopharmaceutical company developing novel…
Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025
REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq: SLNO), a biopharmaceutical company developing…
Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference
Conference is the first-ever international meeting jointly hosted by the Prader-Willi Syndrome Association | USA, the Foundation for Prader-Willi Research,…
Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET
REDWOOD CITY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company…
Soleno Therapeutics: Das Biopharmazie-Unternehmen erhält wichtige FDA-Zulassung für ein Medikaments zur Behandlung einer seltenen genetischen Störung
Soleno ist ein biopharmazeutisches Unternehmen, das neuartige Therapeutika zur Behandlung seltener Krankheiten entwickelt. Mit der FDA-Zulassung von VYKAT XR,…
Soleno Therapeutics im Pivotal-Point-Check: Stifel sieht „Blockbuster-Chance“ durch die Zulassung von Vykat XR zur Behandlung des Prader-Willi-Syndroms!
Soleno Therapeutics hat einen Meilenstein auf dem Markt für seltene Krankheiten erreicht. Die Behandlung mit Diazoxid-Cholin zielt darauf ab,…
Soleno Therapeutics: In No Rush To Join Buying Frenzy Despite Vykat Approval
…
Soleno Therapeutics: PDUFA Extension May Be An Opportunity, But Not For Me
…
Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments
…
Why Soleno Therapeutics Stock Blasted 9% Higher Today
The companys Prader-Willi treatment inched closer to FDA approval.…
Soleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi Syndrome
REDWOOD CITY, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical…
Soleno Therapeutics: 2 New Catalysts To Bring Forth Change For PWS Patients
…
Soleno Therapeutics CFO sells over $298k in company stock By Investing.com
Soleno Therapeutics CFO sells over $298k in company stock…
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical…
Soleno Therapeutics Stands with the Prader-Willi Syndrome Community
This Prader-Willi Syndrome Awareness Day, May 15, join Soleno Therapeutics in sharing messages of hope and kindness for the Prader-Willi…
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a…
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical…
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical…
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
REDWOOD CITY, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical…